Gustavo E. Velásquez
Gustavo E. Velásquez, MD, MPH
Instructor in Medicine, Harvard Medical School, Harvard Medical School
Research Associate in Global Health and Social Medicine
Associate Physician, Division of Infectious Diseases at Brigham and Women's Hospital

Gustavo E. Velásquez, MD, MPH is an associate physician in the Division of Infectious Diseases at Brigham and Women’s Hospital (BWH). He is an instructor in the Department of Medicine and a research associate in the Department of Global Health and Social Medicine at Harvard Medical School. Dr. Velásquez received an MD from the Northwestern University Feinberg School of Medicine and an MPH from the Harvard T.H. Chan School of Public Health. He completed a residency in Global Health Equity and Internal Medicine at Brigham and Women’s Hospital in and a fellowship in Infectious Diseases at Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Velasquez is a prior recipient of the Ronda Stryker and William Johnston Fellowship in Global Health and Social Medicine. At BWH, Dr. Velásquez attends on the inpatient general infectious disease and HIV consultation service and staffs the BWH Tuberculosis Clinic.

Dr. Velásquez's research interest is to develop safe, tolerable, and effective treatment regimens for drug-susceptible and drug-resistant tuberculosis (TB). He has experience in programmatic evaluations of multidrug-resistant tuberculosis (MDR-TB) screening and drug-resistance testing in Peru; in outcomes research evaluating MDR-TB regimen composition and TB/HIV coinfection management in the Russian Federation and Peru; and in a Phase 2B dose-ranging clinical trial of high-dose rifampin for drug-susceptible TB in Peru (HIRIF, ClinicalTrials.gov NCT01408914).

Dr. Velásquez works with Carole Mitnick, ScD and the endTB consortium (endTB.org) as a co-investigator in an ongoing multi-country Phase 3 clinical trial evaluating novel shortened oral regimens for fluoroquinolone-susceptible MDR-TB (endTB, ClinicalTrials.gov NCT02754765) and its pharmacokinetic and pharmacodynamic sub-study (PandrTB, ClinicalTrials.gov NCT03827811). He is a co-investigator in a forthcoming Phase 3 clinical trial for fluoroquinolone-resistant MDR-TB (endTB-Q, ClinicalTrials.gov NCT03896685). Dr. Velásquez is also an investigator in the AIDS Clinical Trials Group’s TB Transformative Science Group.

Quantitative assessment of the activity of antituberculosis drugs and regimens.
Authors: Authors: Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H.
Expert Rev Anti Infect Ther
View full abstract on Pubmed
Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
Authors: Authors: Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD.
Am J Respir Crit Care Med
View full abstract on Pubmed
Outcomes of a Career Development Program for Underrepresented Minority Investigators in the AIDS Clinical Trials Group.
Authors: Authors: Velásquez GE, Huaman MA, Powell KR, Cohn SE, Swaminathan S, Outlaw M, Schulte G, McNeil Q, Currier JS, Del Rio C, Castillo-Mancilla J.
Open Forum Infect Dis
View full abstract on Pubmed
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.
Authors: Authors: Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD.
Am J Respir Crit Care Med
View full abstract on Pubmed
Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis.
Authors: Authors: Velásquez GE, Davies GR, Mitnick CD.
Int J Tuberc Lung Dis
View full abstract on Pubmed
A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept.
Authors: Authors: Jain N, Doyon JB, Lazarus JE, Schaefer IM, Johncilla ME, Agoston AT, Dalal AK, Velásquez GE.
J Gen Intern Med
View full abstract on Pubmed
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
Authors: Authors: Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G.
Antimicrob Agents Chemother
View full abstract on Pubmed
Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.
Authors: Authors: Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD.
Int J Tuberc Lung Dis
View full abstract on Pubmed
Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
Authors: Authors: Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB.
Antimicrob Agents Chemother
View full abstract on Pubmed
Novel Ordered Stepped-Wedge Cluster Trial Designs for Detecting Ebola Vaccine Efficacy Using a Spatially Structured Mathematical Model.
Authors: Authors: Diakite I, Mooring EQ, Velásquez GE, Murray MB.
PLoS Negl Trop Dis
View full abstract on Pubmed